F8 and hemophilia: Notwithstanding the expected difficulties in designing and conducting a randomized controlled trial in hemophilia, the SIPPET study was initiated in 2009, published in 2017 providing definitive answers regarding the different immunogenicity between recombinant and plasma-derived FVIII products (9).